![]() Duration of Adjuvant Chemotherapy for Stage III Colon Cancer: Final Results from the IDEA (International Duration Evaluation of Adjuvant chemotherapy) Collaboration. Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency. Adrenal Gland as a Sanctuary Site for Immunotherapy in Patients with Microsatellite Instability-High Metastatic Colorectal Cancer. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. ![]() Microsatellite-Instability-High Advanced Colorectal Cancer. Pembrolizumab in Microsatellite Instability High Advanced Colorectal Cancer. Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. Fucà G, et al.,Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.KEYNOTE-177 Investigators.Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Gastroenterol Hepatol, 2022, 7, 4-6 Immune checkpoint inhibitors in colorectal cancer: dream and reality. Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study. A PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon André, T et al Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch RepairĪm Soc Clin Oncol Educ Book, 2022, 42, 1-9.Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy - Authors'' reply. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. ![]() Impact of mismatch repair deficiency on tumour regression grade after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma.ĭig Liver Dis, 2022 Jun 29:S1590-8658(22)00548-5. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. Lancet Gastroenterol Hepatol 2022 sous presse Trifluridine/tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy: the phase 3 randomised SOLSTICE study. Principales publications scientifiques du service d'oncologie médicale de l'hôpital Saint Antoine de ces dix dernières années.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |